integralife.com - IART Company Value to Revenue Ratio

Public company logo of Integra LifeSciences Holdings Corporation (IART)

Competition for clinics with medtech giants in the minimally invasive surgery segment is creating pressure, which the GURU.Markets EV/Revenue chart confirms, with the current metric standing at 1671.10. However, Integra LifeSciences (IART) maintains resilience through its status as a global leader in tissue regeneration and the Codman brand, while the deep integration of its tools into operating rooms minimizes switching risks.

IART Integra LifeSciences: EV/Sales Multiple in the range 11/23/2025 - 11/19/2026

IART (Integra): analytical breakdowns and indicator data

Fundamental valuation:Integra LifeSciences IART
Mass-produced product of Integra LifeSciences Corp

The EV/Sales multiple determines the enterprise value of a business, including net debt, per unit of generated revenue. By analyzing the enterprise value-to-revenue trend, an investor assesses the capitalization efficiency of operating flows without the influence of financing structure. A decline in this metric may signal either an undervaluation or a risk of margin compression. For Integra LifeSciences (IART), a high valuation is justified by exceptional pricing power. Its monopoly position in the critical neurosurgical membranes segment makes revenue resilient to market fluctuations.

Competitor analysis for Integra LifeSciences

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Establishment Labs - Business Value to Revenue|BBNX (iLet Bionic Pancreas) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple IRADIMED Corp IRMD|Enterprise Value-to-Revenue Ratio Embecta Corp (EMBC)|Tandem Diabetes Care (TNDM) - Enterprise Value-to-Sales Ratio|Axogen Surgical - Company Value to Revenue|EV/Sales Multiple SI-BONE, Inc. SIBN|Orthofix Medical - EV/Sales Multiple|Enterprise Value to Sales Volume BVS|OrthoPediatrics (KIDS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume TMCI (Treace Corp)|Enterprise Value-to-Revenue Ratio blade.com|Company Value to Revenue Carlsmed Inc (CARL)|EV/Sales Multiple RXST|CLPT - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Stereotaxis, Inc. STXS|STIM: Company Value to Revenue Ratio|SGHT: Company Value to Revenue|Orchestra BioMed Inc. - Enterprise Value-to-Revenue Coefficient|ANIK: EV/Sales Multiple|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio